Reuters logo
5 months ago
BRIEF-Cadila healthcare says zydus gets approval from USFDA to initiate phase II clinical studies of Saroglitazar Magnesium
February 23, 2017 / 7:26 AM / 5 months ago

BRIEF-Cadila healthcare says zydus gets approval from USFDA to initiate phase II clinical studies of Saroglitazar Magnesium

1 Min Read

Feb 23 (Reuters) - Cadila Healthcare Ltd

* Zydus gets approval from USFDA to initiate phase II clinical studies of saroglitazar magnesium in patients with primary biliary cholangitis

* Says randomized double blind phase 2 trial to evaluate saroglitazar magnesium versus placebo Source text - (bit.ly/2l2ii24) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below